14.41
전일 마감가:
$14.55
열려 있는:
$14.4
하루 거래량:
1.58M
Relative Volume:
0.96
시가총액:
$12.03B
수익:
$3.85B
순이익/손실:
$667.93M
주가수익비율:
21.93
EPS:
0.657
순현금흐름:
$142.30M
1주 성능:
-0.83%
1개월 성능:
-5.38%
6개월 성능:
-4.51%
1년 성능:
-10.02%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
명칭
Dr Reddys Laboratories Ltd Adr
전화
-
주소
-
RDY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.41 | 12.09B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
2024-12-19 | 다운그레이드 | Nomura | Buy → Neutral |
2024-01-11 | 다운그레이드 | Jefferies | Buy → Underperform |
2023-08-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
2023-05-18 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
2023-03-17 | 업그레이드 | BofA Securities | Neutral → Buy |
2023-01-30 | 개시 | JP Morgan | Underweight |
2022-11-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
2022-01-03 | 재개 | BofA Securities | Neutral |
2021-07-27 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2021-02-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
2020-09-18 | 업그레이드 | BofA Securities | Neutral → Buy |
2020-09-18 | 업그레이드 | Investec | Sell → Hold |
2020-01-28 | 다운그레이드 | CLSA | Buy → Outperform |
2020-01-27 | 다운그레이드 | CLSA | Buy → Outperform |
2020-01-09 | 업그레이드 | Citigroup | Sell → Buy |
2019-11-04 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2019-09-04 | 업그레이드 | Credit Suisse | Underperform → Outperform |
2019-07-01 | 업그레이드 | Macquarie | Neutral → Outperform |
2019-06-20 | 개시 | Deutsche Bank | Hold |
2019-06-11 | 개시 | Barclays | Equal Weight |
2019-05-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | 업그레이드 | CLSA | Outperform → Buy |
2019-01-17 | 다운그레이드 | Citigroup | Neutral → Sell |
2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | 업그레이드 | CLSA | Underperform → Outperform |
2017-07-28 | 다운그레이드 | CLSA | Underperform → Sell |
2016-07-27 | 다운그레이드 | HSBC Securities | Hold → Reduce |
2016-07-27 | 다운그레이드 | Jefferies | Hold → Underperform |
2016-02-10 | 업그레이드 | Credit Agricole | Underperform → Buy |
2015-11-10 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
Dr Reddys Laboratories Ltd Adr 주식(RDY)의 최신 뉴스
Dr Reddys Q1 Results Preview: Analysts Outlook Mixed, See Double-Digit Growth - NDTV Profit
Asian Stocks Mixed As S&P Asia 50 ADR Index Falls - Finimize
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - MSN
LLY Stock Quote Price and Forecast - CNN
Asian ADRs Retreat As Mixed Results Hit The Market - Finimize
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Morgan Stanley initiates coverage on Dr. Reddy’s stock with Equalweight rating - Investing.com India
Functional Dyspepsia Market Analysis and Forecast, 2025-2035, Competitive Analysis of AstraZeneca, P&G, Takeda, Prestige Consumer Healthcare, Kenvue Brands, Dr. Reddy's, Pfizer, ZERIA, Daewoong - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Mixed Movements In Asian Equities As Some Sectors Shine - Finimize
Full Truck Alliance Co. Ltd. Sponsored ADR (NYSE:YMM) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Mather Group LLC. Buys 3,413 Shares of Haleon PLC Sponsored ADR (NYSE:HLN) - Defense World
Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Holdings Cut by Robeco Institutional Asset Management B.V. - MarketBeat
Asian ADRs Climb With North And South Leaders - Finimize
Dr Reddy’s Breaks Past ₹1,330 Apex: SEBI RA Rajneesh Sharma Sees Trend Shift, Cautions Overbought Zone - Investing.com India
Dr Reddys Laboratories allots Equity shares - Business Standard
RDY’s Market Whiplash: 2.41% YTD Rise, 14.68% Rise in 30 Days - investchronicle.com
SBI Cards to WiproPrashanth Tapse suggests stocks to buy in the short term - Mint
Stocks Showing Rising Market Leadership: Dr. Reddy's Labs ADR Earns 81 RS Rating - Investor's Business Daily
Yatsen And Zai Lab Shine As Asian ADRs Climb In The US - Finimize
Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech By Investing.com - Investing.com Nigeria
Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech - Investing.com Australia
HSBC upgrades Dr. Reddy’s stock rating citing semaglutide prospects - Investing.com Australia
Asian Equities Gain In US Markets' Positive Start - Finimize
Dr. Reddy’s Laboratories Receives USFDA Observations After Recent Inspection - TipRanks
Bank of America Corp DE Buys 1,057,584 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Dr Reddys Laboratories shares climb over 1.1% amid increased trading volume in today's session - Moneycontrol
Axa S.A. Has $1.23 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol
Shares To Buy For Short-term: Analysts recommend 5 largecap, 2 midcap stocks; Britannia, Dr Reddy's, TCS on the list - Zee Business
Wells Fargo & Company MN Has $124,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) - Defense World
Asian Equities Climb Despite Weekly Losses - Finimize
Dr. Reddy’s Earnings: Year-End Numbers Look Solid as Demand and Prescription Trends Remain Resilient - Morningstar
Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks
Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX
Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains
Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com
Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol
Gift Nifty, India ADRs see sharp sell-off following escalation in India-Pakistan conflict - Moneycontrol
Dr Reddys Laboratories Ltd Adr (RDY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):